IL2 and B-cell chronic lymphocytic leukemia: Maharaj et al. [166] demonstrated in their study that administering low-dose IL-2 could prolong remission in patients with chronic lymphocytic leukemia (CLL) by enhancing the activity of residual T cells and NK cells.